Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
The first patient has been treated in a phase 1/2 clinical trial of an experimental ... treatment-resistant malignant melanoma. PD-L1 is a cell surface receptor expressed on both tumour and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback